Zhejiang Int'l Group Co

Zhejiang Int'l Group Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Zhejiang Int'l Group Co (000411.SZ) as of Nov 19, 2026 is 7.08. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 8.70 — a change of -18.62% (lower).

EV/EBITDA

7.08

YoY

-18.62%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Zhejiang Int'l Group Co is 2025 7.08 . EV/EBITDA (Enterprise Value to EBITDA) of Zhejiang Int'l Group Co was 2024 8.70 . It decreases by -18.62% lower compared to the previous year.

The Zhejiang Int'l Group Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
22.89 CNY
Jan 1, 2019
14.87 CNY
Jan 1, 2020
15.10 CNY
Jan 1, 2021
12.92 CNY
Jan 1, 2022
11.71 CNY
Jan 1, 2023
9.13 CNY
Jan 1, 2024
8.70 CNY
Jan 1, 2025
7.08 CNY
The Zhejiang Int'l Group Co EV/EBITDA history
YEAREV/EBITDAYoY
7.08-18.62%
8.70-4.65%
9.13-22.08%
11.71-9.39%
12.92-14.41%
15.10+1.58%
14.87-35.05%
22.89-9.27%
25.23+3.85%
24.29-23.70%
31.84-10.27%
35.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zhejiang Int'l Group Co Stock analysis

What does Zhejiang Int'l Group Co do? Zhejiang Int'l Group Co., Ltd. generates revenue by wholesaling and retailing pharmaceuticals and medical devices. The company buys products from pharmaceutical manufacturers or suppliers and distributes them to distributors, medical institutions, and pharmacies. It also sells directly to consumers through retail terminals. The firm operates exclusively within Mainland China, serving a broad customer base across the healthcare sector. The business model relies on purchasing products from manufacturers or suppliers, then reselling them through wholesale channels to medical institutions and pharmacies, or via retail terminals to end consumers. This dual-channel approach allows the company to reach both institutional and individual customers without direct manufacturing involvement. Mainland China represents the sole market for all its operations. Zhejiang Int'l Group Co., Ltd. focuses on pharmaceutical and medical device distribution, targeting distributors, medical institutions, and pharmacies as key wholesale clients. Retail sales are directed toward consumers through its own retail terminals. The company does not engage in manufacturing, instead acting as a middleman between producers and end users within the Chinese healthcare market. Zhejiang Int'l Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zhejiang Int'l Group Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Zhejiang Int'l Group Co is 7.08 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Zhejiang Int'l Group Co changed from 8.70 to 7.08, representing a -18.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Zhejiang Int'l Group Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Zhejiang Int'l Group Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Zhejiang Int'l Group Co

All Key Metrics — Zhejiang Int'l Group Co